Alumis (ALMS) Projected to Announce Earnings on Thursday

Alumis (NASDAQ:ALMS) is expected to be issuing its Q3 2026 resultson Thursday, November 12th. Analysts expect Alumis to post earnings of ($0.73) per share and revenue of $1.90 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Alumis (NASDAQ:ALMS) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.34). Alumis had a negative net margin of 5,933.46% and a negative return on equity of 93.15%. The business had revenue of $1.66 million during the quarter, compared to analysts’ expectations of $3.65 million. On average, analysts expect Alumis to post ($2.95) EPS for the current fiscal year and ($2.84) EPS for the next fiscal year.

Alumis Price Performance

Shares of Alumis stock opened at $6.55 on Tuesday. The firm has a fifty day moving average price of $7.81 and a 200 day moving average price of $20.85. Alumis has a 1 year low of $4.59 and a 1 year high of $31.35. The stock has a market cap of $847.77 million, a PE ratio of -1.70 and a beta of -0.28.

Insider Buying and Selling

In other Alumis news, Director Srinivas Akkaraju sold 96,131 shares of Alumis stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $10.55, for a total value of $1,014,182.05. Following the completion of the transaction, the director owned 2,025,493 shares of the company’s stock, valued at approximately $21,368,951.15. The trade was a 4.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 99,754 shares of company stock worth $1,037,804 in the last quarter. 33.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on ALMS. Robert W. Baird set a $27.00 price target on shares of Alumis in a report on Tuesday, September 1st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a research note on Wednesday, September 16th. Benchmark reissued a “buy” rating on shares of Alumis in a report on Monday, October 5th. Oppenheimer lowered their target price on Alumis from $55.00 to $37.00 and set an “outperform” rating on the stock in a research note on Wednesday, September 2nd. Finally, Guggenheim lowered Alumis from a “buy” rating to a “neutral” rating in a report on Thursday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.27.

About Alumis

Alumis is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. The company uses data and computational tools to support the discovery and development of targeted treatments.

Its lead investigational program, ESK-001, is an oral, selective TYK2 inhibitor being studied for conditions including plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing other drug candidates for immune-mediated diseases. These medicines remain in clinical development and are not approved for commercial use.

Alumis was formed in 2024 through the combination of Esker Therapeutics and Kintara Therapeutics and is based in South San Francisco, California.